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Abstract (150 words): 
Selected vulnerability of neurons in Huntington’s disease (HD) suggests alterations in a cellular 
process particularly critical for neuronal function. Supporting this idea, pathogenic Htt (polyQ-Htt) 
inhibits fast axonal transport (FAT) in various cellular and animal HD models (mouse and squid), 
but the molecular basis of this effect remains unknown. Here we show that polyQ-Htt inhibits FAT 
through a mechanism involving activation of axonal JNK. Accordingly, increased activation of JNK 
was observed in vivo in cellular and animal HD models.  Additional experiments indicate that 
polyQ-Htt effects on FAT are mediated by the neuron-specific JNK3, and not ubiquitously 
expressed JNK1, providing a molecular basis for neuron-specific pathology in HD. Mass 
spectrometry identified a residue in the kinesin-1 motor domain phosphorylated by JNK3, and this 
modification reduces kinesin-1 binding to microtubules. These data identify JNK3 as a critical 
mediator of polyQ-Htt toxicity and provides a molecular basis for polyQ-Htt-induced inhibition of 
FAT. 
 
 
 
 
 
 
 
 
Huntington’s disease (HD) is an autosomal dominant, adult-onset neurodegenerative disease1. 
Patients with a single mutant huntingtin (Htt) gene develop symptoms in midlife with 100% 
penetrance. The mutation is a toxic gain of function, because loss of a single gene has no phenotype 
and the Htt-null is embryonic lethal2. The disease-causing mutation is expansion of a CAG 
trinucleotide repeat encoding a polyglutamine (polyQ) tract and polyQ-expansions in other genes 
may also lead to adult-onset neurodegeneration, but pathogenic mechanisms remained uncertain2. 
Several lines of evidence indicated that pathogenesis in Huntington’s disease include inhibition of 
fast axonal transport (FAT)3. Although consequences of FAT inhibition in neurons are well 
established, mechanisms underlying inhibition of FAT by pathogenic Htt (polyQ-Htt) were 
unknown.  Proposed mechanisms included wild-type Htt (WT-Htt) loss of function4, physical 
blockade by polyQ-Htt aggregates5,6, sequestration of motor molecules4, 6, and misregulation of 
FAT3, 7, 8.   
We found no evidence for direct interactions of conventional kinesin and cytoplasmic dynein 
(CDyn) with WT-Htt or polyQ-Htt in vivo.  However, analysis of HD models showed that polyQ-
Htt, but not WT-Htt increased cJun N-terminal kinase (JNK) activity. Pharmacological and peptide 
inhibitors of JNK prevented inhibition of FAT by polyQ-Htt. Surprisingly, only a subset of JNK 
isoforms inhibited FAT, with neuron-specific JNK3 selectively mimicking effects of polyQ-Htt. In 
vitro phosphorylation and mass spectrometry studies showed that JNK3, but not ubiquitously 
expressed JNK1, phosphorylated Ser176 in the kinesin heavy chain (kinesin-1, KHC) motor 
domain. Consistent with this location, phosphorylation of kinesin-1 by JNK3 inhibited kinesin 
binding to microtubules and translocation along axons.  Our data indicate that polyQ-Htt inhibits 
FAT by a mechanism involving axonal JNK3 activation and phosphorylation of kinesin-1. 
 
 
RESULTS: 
Htt does not interact with microtubule-based motors.  PolyQ-Htt inhibits FAT in various 
experimental systems, including Drosophila4, 5, neuroblastoma cells9, 10, and isolated squid 
axoplasm8, but the molecular basis of inhibition was undetermined3.  Interactions have been 
reported between exogenously overexpressed Htt and conventional kinesin4 or various subunits of 
cytoplasmic dynein (CDyn)9-11. Alternatively, polyQ-expansion was proposed to affect Htt function 
as a scaffolding protein for molecular motors9, 12. However, interactions between endogenous WT-
Htt and molecular motors were not evaluated. We tested interactions by immunoprecipitation and 
subcellular fractionation (Fig. 1), as previously described13, 14. To avoid overexpression-related 
artifacts, we used brain tissue from 14 month-old homozygous HdhQ109 knock-in mice and age-
matched controls, which express polyQ-Htt or WT-Htt at endogenous levels15.   At this age, both 
polyQ-Htt-derived nuclear inclusions and insoluble aggregates are found in the brains of HdhQ109 
knock-in mice15. Conventional kinesin is a heterotetramer composed of two heavy chains (kinesin-1, 
KHC) and two light chains (KLC)13. Antibodies recognizing kinesin-1 (H2) effectively 
immunoprecipitated kinesin-1 from detergent-soluble brain lysates independent of genotype (Fig. 
1A). Kinesin-1 antibodies co-immunoprecipitated KLCs13, 14, but failed to co-immunoprecipitate 
either WT-Htt or polyQ-Htt. Similarly, antibodies against DIC co-immunoprecipitated DHC16, but 
did not immunoprecipitate WT-Htt or polyQ-Htt (Fig. 1A).  Conversely, anti-Htt antibodies 
immunoprecipitated Htt from both wild type and homozygous HdhQ109 knock-in mouse brain 
lysates, but no kinesin-1, KLC, DIC nor DHC could be detected in Htt immunoprecipitates.  
To detect substoichiometric amounts of Htt associated with conventional kinesin or CDyn, we 
performed three rounds of immunoprecipitation, sufficient to nearly deplete mouse brain lysates of 
kinesin-1 (Fig. 1B) or DIC (Supplemental Fig. 1B). As in previous studies, marked reductions in 
kinesin-1 and KLC levels occurred with each immunoprecipitation cycle13, 14. However, Htt levels 
remained unchanged after three immunoprecipitation cycles, regardless of genotype.  
PolyQ-Htt was reported to sequester molecular motors in detergent-insoluble aggregates when 
overexpressed4, 6. To evaluate this at endogenous levels, brain lysates from wild type and 
homozygous HdhQ109 knock-in mice were fractionated into detergent-soluble and insoluble 
fractions, and partitioning of Htt and molecular motors analyzed by immunoblot (Supplemental 
Fig. 1). WT-Htt and polyQ-Htt levels were comparable in detergent soluble and insoluble fractions, 
but the bulk of kinesin-1, DHC and DIC were detergent-soluble. Molecular motor levels were 
similar for wild type and homozygous HdhQ109 knock-in mice. Thus, WT-Htt and polyQ-Htt 
expressed at endogenous levels do not interact with molecular motors; so FAT inhibition associated 
with polyQ-Htt must result from a different mechanism.  
JNK activity mediates FAT defects induced by polyQ-Htt. Effects of WT-Htt and polyQ-Htt on 
FAT were assayed in isolated squid axoplasm8. Perfusion of WT-Htt showed no effect (Fig. 2A), 
but perfusion of polyQ-Htt at a concentration 100-1000 times lower than kinesin-13, 8 dramatically 
inhibited both anterograde (kinesin-dependent) and retrograde (CDyn-dependent) FAT (Fig. 2B). In 
axoplasm, anterograde FAT of membrane-bounded organelles (MBOs) depends primarily upon 
conventional kinesin17, which is regulated by phosphorylation7, 18, 19. Multiple kinase activities may 
be deregulated in Huntington’s disease20-22 and inhibition of FAT by pathogenic androgen receptor 
(polyQ-AR) depends on JNK activation in axoplasm7. This led us to evaluate the role of JNK in 
polyQ-Htt-induced inhibition of FAT. Axoplasmic JNK activity was assessed in vitro using 
recombinant GST-cJun, a well-characterized JNK substrate23 (Fig. 2C). Incubation with axoplasm 
lysates produced a time-dependent increase in cJun phosphorylation at JNK sites (serines 63/73), 
reflecting basal JNK activity in axoplasm. Pharmacological properties of endogenous axoplasmic 
JNK were validated with two JNK inhibitors (SP600125 and JIP peptide)23. SP600125 is a 
pharmacological inhibitor of JNK, showing >20-fold selectivity for JNK over a range of kinases24. 
JIP peptide (JNK inhibitor I) is a 20-amino acid peptide derived from a JNK-binding protein, which 
selectively inhibits JNK, but not p38 activity25. Both SP600125 and JIP peptide dramatically 
inhibited cJun phosphorylation, suggesting common pharmacological properties between squid and 
mammalian JNKs (Fig. 2C).  
As with polyQ-AR7, co-perfusion of axoplasm with polyQ-Htt and either SP600125 (500nM, Fig. 
2D) or JIP peptide (100 nM, Fig. 2E) blocked effects of polyQ-Htt on FAT, suggesting that polyQ-
Htt inhibition of FAT requires JNK activity. In cultured cells, pharmacological inhibitors of histone 
deacetylase (HDAC) were reported to rescue defects in FAT induced by polyQ-Htt by increasing 
tubulin acetylation26. However, coperfusion of polyQ-Htt with the HDAC6 inhibitor BC-6-25 
(10µM) (Compound 227) did not prevent inhibition of FAT by polyQ-Htt in axoplasm (Fig. 2F). 
Thus, inhibition of FAT by polyQ-Htt involves activation of endogenous axonal JNK. 
PolyQ-Htt expression increases JNK activity. Vesicle motility and biochemical assays indicated 
that JNK activity mediates polyQ-Htt inhibition of FAT. JNK activation involves phosphorylation 
by upstream mitogen-activated protein kinase kinases (MKKs, typically MKK4/MKK7)28. Effects 
of polyQ-Htt on JNK phosphorylation were evaluated in cellular and animal Huntington’s models, 
using antibodies against total JNK (pan-JNK, phosphorylation-independent) or against 
phosphorylated, catalytically active JNKs (pJNK). Effects of polyQ-Htt expression on JNK 
activation were evaluated qualitatively after transient transfection (Fig. 3A). NSC34 neuroblastoma 
cells were transfected with WT-Htt (Q18) or polyQ-Htt (Q56)29. Immunoblots show exogenous Htt 
constructs were expressed at levels similar to endogenous Htt. Pan-JNK and pJNK antibodies 
recognized two major immunoreactive bands (p46 and p54) corresponding to mammalian JNKs in 
NSC34 cell lysates and striatal mouse tissue (Fig. 3A, C)30. Expression levels for both pan-JNK 
immunoreactive bands were comparable in cells expressing WT-Htt and polyQ-Htt. However, 
pJNK antibodies showed a clear increase in p54 immunoreactivity in cells expressing polyQ-Htt 
(Fig. 3A), consistent with previous reports20, 22, 31.  
Differential activation of p54 and p46 JNKs led us to evaluate their identity using antibodies 
selective for JNK1, JNK2 and JNK3. Specificity was validated by immunoblotting against 
recombinant GST-tagged JNKs, as well as brain lysates from mice with ablation of individual JNK 
genes30 (Fig. 3B). Anti-JNK1, 2 and 3 antibodies selectively recognized their target JNK (Fig. 3B), 
showing no immunoreactivity against brain lysates from mice deleted for that JNK gene (Fig. 3B). 
We examined JNK expression in striatal tissue from 8 month-old wild-type, heterozygous and 
homozygous HdhQ109 mice (Fig. 3C). HdhQ109 knock-in mice are asymptomatic at this age15. 
Phosphorylation of Akt at Ser473 was not affected (Fig. 3C) and pan-JNK immunoreactivity was 
comparable, regardless of genotype. However, pJNK immunoreactivity was significantly greater in 
lysates from heterozygous and homozygous HdhQ109 knock-in mice, relative to wild-type (Fig. 3C). 
Cortical lysates gave similar results (data not shown). P54 and p46 were differentially activated as 
observed in transfected cells. P54 showed greater increases in pJNK immunoreactivity than p46 in 
HdhQ109 mice relative to wild type in both striatum (Fig. 3E) and cortex (not shown). Consistent 
with autosomal dominance of HD, JNK activation increased in both heterozygous and homozygous 
HdhQ109 mice, but activation was greater in homozygotes than heterozygotes.  
Immunoreactivity corresponding to p54 and p46 in NSC34 and striatal lysates mainly corresponded 
to JNK2/3 and JNK1, respectively (Fig. 3D). An activation ratio (Fig. 3E) was defined as the ratio 
of pJNK/JNK immunoreactivities for JNK1 (p46) or JNK2/3 (p54). Both JNK1 and JNK2/3 
activation ratios were elevated in heterozygotes and homozygotes relative to wild-type brain. JNK1 
activity in wild-type mice was 1.097±0.146 (mean ± SEM), whereas JNK1 activity was 
1.527±0.061 in homozygotes and 1.342±0.133 in heterozygotes HdhQ109 mice  (n = 4 in all cases). 
Differences in JNK1 activity between wild-type and HdhQ109 homozygotes was significant at p≤0.05 
in a pooled t-test, but failed to reach significance between wild-type and HdhQ109 heterozygotes. 
JNK2/3 activity for wild-type mice was 0.242±0.012 (mean ± SEM), whereas JNK2/3 activity was 
0.590±0.055 for homozygotes and 0.440±0.035 for heterozygotes (n = 4 in all cases). JNK2/3 
activity increased in both homozygote and heterozygote HdhQ109 mice relative to WT mice and 
differences were significant at p≤0.01 in a pooled t-test.  Both JNK1 and JNK2/3 activities were 
increased by polyQ-Htt, but polyQ-Htt had a greater effect on JNK2/3 than JNK1.  
JNK3 mediates effects of polyQ-Htt on FAT. JNK2/3 is selectively activated in neurons by stress 
in the presence of constitutive JNK1 activity32, 33. Based on differential activation of JNKs (Fig. 3A–
B), effects of specific JNK isoforms on FAT were evaluated. SB203580 differentially affects JNK1 
and JNK2/3 in vitro24. At 10µM concentration, SB203580 preferentially inhibits JNK2/3; JNK1 
inhibition requires a 10-fold higher concentration23. Axoplasmic JNK activity was almost eliminated 
by 100µM SB203580, but significant JNK activity remained with 10µM SB203580 (Fig. 4A). 
However, 10µM SB203580 completely prevented inhibition of FAT by polyQ-Htt (Fig. 4B), 
suggesting that polyQ-Htt effects involved JNK2 or JNK3. Significantly, 10µM SB203580 also 
prevented inhibition of FAT by polyQ-AR7. JNK isoforms were distinguished using biochemical 
approaches. JSAP1 is a scaffold protein regulating JNK activation34. Four JSAP1 isoforms were 
identified (a,b,c and d), all containing a 17-amino acid JNK binding domain (JBD) homologous to 
the JIP peptide (Fig. 4C). A 31 amino acid insert in JSAP1c/JSAP1d selectively reduces binding to 
JNK334. As a result, JSAP1d binds JNK3 with lower affinity than JSAP1a, and inhibits JNK3 less 
efficiently34. Recombinant JSAP1a (amino acids 115–233) and JSAP1d (amino acids 115–264) 
polypeptides were expressed and purified, then co-perfused at 5µM with polyQ-Htt (Fig. 4D). 
Perfusion of JSAP1a and JSAP1d alone had no effect on FAT (not shown). As with JIP peptide 
(Fig. 2E), co-perfusion of polyQ-Htt and JSAP1a completely prevented inhibition of FAT by 
polyQ-Htt (Fig. 4D). In contrast, JSAP1d reduced, but did not eliminate polyQ-Htt effects on FAT 
(Fig. 4E), suggesting JNK3 mediates polyQ-Htt effects in FAT.  
Effects of specific JNK isoforms on FAT were evaluated in isolated axoplasm (Fig. 5). The activity 
of recombinant JNKs was normalized in vitro using c-Jun as substrate (data not shown). JNK1 
(200nM) did not affect FAT (Fig. 5A), consistent with reports of constitutive JNK1 activity in 
neurons32, 33. JNK2 (100nM) decreased anterograde FAT rates slightly (1.25 µm/sec, compared to 
1.6 µm/sec for control buffer; P≤ 0.01, two-sample t-test) (Fig. 5B), but did not affect retrograde 
FAT (Fig. 5D). As with polyQ-Htt perfusion (Fig. 5D), JNK3 (100nM) inhibited both directions of 
FAT (Fig. 5C). Quantitative analysis showed that JNK3 inhibited both anterograde (0.9 µm/sec; 
compared to 1.6 µM/sec in control buffer) and retrograde (1.25 µm/sec, compared to 1.4 µm/sec in 
control buffer) FAT at p≤ 0.01, two-sample t-test, suggesting that JNK3 is principally responsible 
for polyQ-Htt effects on FAT. 
JNK3 phosphorylates kinesin-1 at Ser176. JNK3 phosphorylated kinesin-1, but not KLCs7. Using 
liquid chromatography tandem mass spectrometry (LC/MS/MS) we mapped residues in kinesin-1 
phosphorylated by JNK3 (Fig. 6 and Supplemental Fig. 2). Kinesin-1 constructs encompassing the 
first 584 amino acids of kinesin-1C (KHC584) were phosphorylated in vitro with JNK3 (Fig. 6B)7 
and compared to non-phosphorylated KHC584. Phosphorylated polypeptides were digested with 
trypsin directly for LC/MS/MS analysis or for phosphopeptide enrichment by IMAC35 and 
LC/MS/MS analysis (Supplemental Fig. 2). Identification of mass spectrometry-generated peptides 
used the SEQUEST algorithm. KHC584 identity was confirmed by identification of multiple kinesin-
1C peptides (coverage of 72%) (Supplemental Fig. 2). Residual phosphorylation of several 
peptides was detected (not shown), but using analysis of protease cleavage sites, MS spectra, cross 
correlation (X-corr) as well as delta correlation (dCn) values, a unique peptide corresponding to 
amino acids 173-188, was identified with unequivocal evidence of phosphorylation by JNK3  (Fig. 
6A, and Supplemental Fig. 2). Phosphatase treatment reduced the phosphorylated peak intensity 
compared to neighboring peaks (not shown). This JNK3-phosphorylated peptide was within the 
kinesin-1c motor domain and contained two serines (Fig. 6A). LC/MS/MS allowed precise mapping 
of the specific serine residue carrying the phosphorylation. Tandem mass spectrometry analysis by 
collision-induced dissociation (CID) indicated that phosphorylation occurs on Ser176, but not 
Ser175 (Fig. 6 and Supplemental Fig. 2). Presence of a proline residue adjacent to Ser176 (a 
hallmark of JNK substrates) supported identification of Ser176 as the JNK3 phosphorylation site. 
Mass spectrometric analysis of JNK1-phosphorylated KHC584 did not reveal phosphorylation at this 
site (Supplemental Fig. 3), consistent with differential effects of JNK1 and JNK3 on FAT (Fig. 
5A, C). To confirm ESI-LC/MS/MS analysis, site-directed mutagenesis substituted alanine for 
either Ser175 or Ser176 of KHC584 (KHC584-S175A and KHC584-S176A). Bacterially-expressed 
mutant proteins were purified (Fig. 6B), then phosphorylated in vitro with JNK3, and 32P 
incorporation analyzed by Phosphorimaging. Phosphorylation of KHC584-S176A, but not KHC584-
S175A, was reduced relative to wild-type KHC584 by ≈30% (KHC584-WT, Fig. 6B). Ser176 is 
conserved among squid, mouse and human kinesin-1s (Supplemental Fig. 4A). Levels of 32P 
incorporated in KHC584-S176A were consistent with mass spectrometry findings showing partial 
phosphorylation of KHC584 in vitro at non-conserved residues outside the motor domain (not 
shown). Ser176 phosphorylation was also detected in kinesin-1 immunoprecipitated from mouse 
brain (not shown). Together, these data identified Ser176 as a major kinesin-1 residue 
phosphorylated by JNK3. 
Ser176 phosphorylation affects kinesin-1 function. Effects of polyQ-AR on FAT involved JNK 
activation, increased kinesin-1 phosphorylation and reduced microtubule binding of kinesin-17. 
Ser176 localizes to loop 8, a sequence within the motor domain of kinesin-1 implicated in kinesin-1 
interaction with microtubules (Supplemental Fig. 4B)36, suggesting its phosphorylation might 
affect kinesin-1 binding to microtubules. NSC34 cells were transiently transfected with WT-Htt, or 
polyQ-Htt (see Fig. 3A). Total kinesin-1 levels were comparable for untransfected, WT-Htt, and 
polyQ-Htt-expressing cells (Fig. 7A). However, microtubule-binding assays using the non-
hydrolysable ATP analog AMP-PNP7 revealed a reduction in kinesin-1 binding to microtubules in 
polyQ-Htt-expressing cells relative to WT-Htt-expressing cells (Fig. 7A). Similar effects were 
observed when using immortalized striatal cell lines derived from wild type and HdhQ109 mice (not 
shown). This was consistent with reduced kinesin-1 binding to microtubules in cells expressing 
polyQ-AR7.  
Recombinant KHC584 was incubated with 100µM radiolabeled 32P-γATP in the presence or absence 
of active JNK3 (Fig. 7B), then incubated with purified microtubules in the presence of AMP-PNP 
(2 mM) or 2 mM ATP (to control for non-specific pelleting, not shown). Microtubule pellets (P) 
and corresponding supernatants (SN) were analyzed by immunoblot to visualize non-
phosphorylated KHC584 and autoradiography to visualize JNK3-phosphorylated KHC584. In the 
presence of AMP-PNP, kinesin-1 forms a rigor structure with microtubules13. Virtually all non-
phosphorylated KHC584 partitioned with microtubules by immunoblot (Fig. 7B), but a large fraction 
of JNK3-phosphorylated KHC584 remained in the SN (Fig. 7B), suggesting that phosphorylation of 
kinesin-1 by JNK3 inhibits kinesin-1 binding to microtubules. The presence of JNK3-
phosphorylated KHC584 in P fractions was consistent with residual phosphorylation at residues 
outside the motor domain. JNK-3 phosphorylation of kinesin-1 reduced binding to microtubules 
with AMP-PNP by ≈50% (Supplemental Fig. 5).  
Effects of S176 phosphorylation on kinesin-1 motility in vivo were assessed by expressing GFP-
tagged, truncated kinesin-1 constructs in cultured hippocampal neurons (Fig. 8).  When expressed 
in hippocampal cells, a GFP-tagged kinesin-1 construct (KHC560-GFP -WT) selectively translocates 
to axon distal ends and accumulates, but not in dendrites, indicating that this motor translocates 
preferentially along axonal microtubules37. KHC560-GFP-WT translocation is so efficient that little 
or no fluorescence can be detected within cell bodies or along axons37. To evaluate whether S176 
phosphorylation affects kinesin translocation efficiency, we compared localization of 
phosphorylation-mimicking construct KHC560-GFP-S176E and its unphosphorylatable counterpart 
KHC560-GFP-S176A to that of KHC560- GFP-WT by quantitative fluorescence microscopy (Fig. 
8A–F).   Much less phosphomimetic KHC560-GFP-S176E construct accumulated at axonal tips than 
the KHC560-GFP-WT construct (56 + 2% vs. 87 +3%, respectively, mean + SEM; T-test, p < 
0.0001) (Fig. 8G), with more KHC560- GFP- S176E fluorescence in cell bodies and faint staining of 
neurites (Fig. 8C), the expected pattern if a significant fraction of phosphomimetic kinesin-1 were 
distributed like a soluble protein.  Slightly less KHC560-GFP-S176A accumulated at axon tips (79% 
+ 2%) compared to KHC560- GFP-WT, but accumulations were still significantly higher than 
KHC560-GFP-S176E (t-test, p<0.0001) (Fig. 8G). Thus, a mutation of Ser176 mimicking 
phosphorylation reduces efficiency of processive kinesin-1 translocation in cultured neurons.  
 
DISCUSSION 
Despite ubiquitous expression of Htt, neuronal cells are uniquely vulnerable to the toxic gain-of-
function in polyQ-expansion, suggesting that processes critical for proper neuronal function and 
survival are selectively altered in HD3. Axonal transport is essential for neurons, due to their large 
size and complex functional architecture 3. Significantly, alterations in kinesin-1 function and 
regulation are associated with various human neuropathologies3, 7, 38-40. 
Several reports link FAT inhibition to pathogenesis in HD4, 5, 8 10 and other polyQ-expansion 
diseases3, 7. For example, overexpression of polyQ-Htt in cultured cells10 and Drosophila4, 5 leads to 
reduced transport and accumulation of vesicular cargos within axons. PolyQ-Htt and polyQ-AR, 
two otherwise unrelated proteins, similarly inhibit FAT vesicle motility in isolated axoplasm 
independently of changes in gene transcription or aggregate formation7, 8.  Such observations 
implicate FAT defects in HD pathogenesis, which would partially explain the selective vulnerability 
of neurons in HD and other polyQ-expanded diseases3.  
Several models were proposed to explain the inhibition of FAT induced by polyQ-Htt. Some 
require physical interactions between Htt and conventional kinesin41 or CDyn subunits9, 10, 12. PolyQ-
Htt aggregates were proposed to sequester molecular motors4 6, or physically block FAT5, 42.  
Alternatively, Htt mutations were suggested to interfere with normal functions of Htt as a scaffold 
linking molecular motors to transported cargoes9, 10 11, or to affect the subunit composition and 
function of molecular motors12. However, axoplasm experiments indicated that polyQ-Htt inhibited 
FAT at concentrations 100-1000 fold lower than molecular motors, suggesting activation of 
enzymatic activities3, 7, 8.  
Cell fractionation and immunoprecipitation evaluated interactions between Htt and molecular 
motors in brain tissue from wild-type and homozygous HdhQ109 mice. Regardless of genotype, 
similar levels of full-length Htt were found in detergent-soluble (S) and detergent-insoluble (I) 
fractions. In contrast, KHCs, KLCs, DIC and DHC levels were much higher in soluble fractions, 
suggesting that most molecular motors are not sequestered by polyQ-Htt. Unlike experiments 
involving Htt overexpression, immunoprecipitation failed to detect interactions between 
endogenous Htt and kinesin41 or CDyn12 (Fig. 1). Detection of KLCs in KHC- and DHC in DIC-
immunoprecipitates confirmed that physiologically relevant protein complexes were preserved13, 14. 
Such observations are inconsistent with models in which polyQ-Htt inhibits FAT through direct 
interactions with molecular motors.  
Another model proposed that pathogenic polyQ-Htt activates neuronal regulatory pathways that 
affect FAT3. Kinesin-1 and CDyn are regulated by phosphorylation of specific motor subunits7, 18. 
Kinase activities that regulate FAT, including GSK-343; Akt44, and JNK20, 22, 45 are altered in 
Huntington’s and polyQ-AR activates JNK7. JNK inhibitors blocked polyQ-Htt effects on FAT and 
JNK activation was documented in polyQ-Htt-expressing cells and HdhQ109 mice (Fig. 3). JNK 
activation was more pronounced in homozygous HdhQ109 mice than heterozygous littermates, but 
increased in both, consistent with autosomal dominant inheritance of HD.   JNK activation in 
presymptomatic HdhQ109 mice indicated that this change represents an early event in HD. 
Mammals have three JNK genes (JNK1, JNK2 and JNK3)46. Analysis of JNK in HdhQ109 mice and 
polyQ-Htt-transfected cells indicated that polyQ-Htt increased JNK2/3 activity more than JNK1 
(Fig. 3), consistent with reports showing constitutive JNK1 activity and selective JNK2/3 activation 
in neurons with stress32, 33. This prompted us to examine roles for specific JNK isoforms mediating 
polyQ-Htt effects on FAT. SB203580 inhibits JNK2/3 at 10µM, but JNK1 inhibition requires 
≥100µM23. Significant JNK activity (presumably JNK1) remains in axoplasms treated with 10µM 
SB203580 (Fig. 4A), but 10µM SB203580 prevented polyQ-Htt effects on FAT (Fig. 4B), 
suggesting that polyQ-Htt effects on FAT involve JNK2/3. JSAP1 polypeptides further supported a 
role for JNK3, because JSAP1a, which inhibits all JNKs, preserved FAT effectively, but JSAP1d, 
with a 31- amino acid insert that selectively interferes with JNK3 binding34 did not (Fig. 4D–E).  
To evaluate the role of individual JNKs on FAT, effects of active recombinant JNK1, JNK2 and 
JNK3 on FAT were evaluated in axoplasm. Active JNK1 had no effect on FAT (Fig. 5A), 
consistent with constitutive JNK1 activity in axons32, 33 (Fig. 4A). JNK2 produced a selective, 
moderate effect on anterograde FAT, but no effect on retrograde FAT. In contrast, JNK3 effects on 
FAT paralleled those of polyQ-Htt by inhibiting both anterograde and retrograde FAT. Although 
JNK2 may contribute, JNK3 appears to primarily mediate polyQ-Htt effects on FAT. Notably, 
JNK3 is preferentially expressed in nervous tissues47 and polyQ-Htt pathology is restricted to 
neurons.  
To provide a molecular basis for FAT inhibition by JNK3, relevant phosphorylation sites were 
identified. Mass spectrometry mapped JNK3 phosphorylation of kinesin-1 to S176, a conserved 
residue in the motor domain (Fig. 6A, Supplemental Fig. 2–3). S176 was also modified in kinesin-
1 immunoprecipitated from mouse brain (not shown). Mutagenesis studies confirmed that JNK3 
phosphorylated Ser176 (Fig. 6B). JNK1 did not phosphorylate kinesin-1 at Ser176 (Supplemental 
Fig. 3), consistent with unique substrate preferences for JNK348. Ser176 was conserved among 
squid, mouse and human kinesin-1s (Supplemental Fig. 4A), validating the squid axoplasm model. 
Collectively, these data demonstrate that JNK3 activity is elevated in brains of HdhQ109 mice and 
axoplasm perfused with polyQ-Htt (Fig. 3–4); that JNK3 phosphorylates kinesin-1 at Ser176 (Fig.6 
and Supplemental Fig. 2–3), and that Ser176 modification is sufficient to inhibit trafficking of 
kinesin-1 (Fig. 8). Antibodies selective for this epitope are under development and should allow us 
to quantify the fraction of neuronal kinesin-1 modified by JNK3 in HD brains.  
Based on the Ser176 position within the motor domain36, we evaluated effects of JNK3 
phosphorylation on kinesin-1 binding to microtubules. JNK3-treated recombinant kinesin-1 and 
kinesin-1 in polyQ-Htt-transfected cells exhibited reduced binding to microtubules (Fig. 7). Further, 
pseudophosphorylation at Ser176 dramatically decreased kinesin-1 translocation in vivo (Fig. 8), 
indicating that Ser176 phosphorylation interferes with kinesin-1 function.  
Our results suggest that polyQ-Htt inhibits FAT by activation of axonal JNKs. Additionally, JNK 
activation by polyQ-Htt is also consistent with changes in transcription49, and JNKs can be pro-
apoptotic30 (Supplemental Fig. 6). Significantly, JNK3, and not JNK1, activity mediated polyQ-Htt 
effects on FAT, providing a partial explanation for selective neuronal vulnerability in HD. JNK1 
and JNK2 are ubiquitously expressed, whereas JNK3 is selectively expressed in brain and testes47. 
Identification of kinesin-1 as a novel JNK3 substrate provided a molecular basis for changes in FAT 
consistent with neuron-selective pathology of polyQ-Htt.  
In sum, neuronal JNK3 is activated by polyQ-Htt. JNK3 in turn phosphorylates kinesin-1, 
decreasing its ability to bind microtubules and move cargoes in FAT (Fig. 8 and Supplemental Fig. 
6). Identification of Ser176-phosphorylated kinesin-1 in normal mouse brain suggests a role of 
JNK3 in a normal pathway for regulating kinesin and delivering specific MBO cargoes to particular 
neuronal domains. Increased activation of this pathway by polyQ-Htt would lead to reductions in 
kinesin-based transport, deficits in synaptic and axonal function, and eventual dying-back neuronal 
degeneration3. Inhibition of JNK3 sufficed to prevent inhibition of FAT due to polyQ-Htt. These 
results suggest that elevation of JNK activity and consequent inhibition of FAT may represent 
primary pathogenic events in Huntington’s disease. Further studies should illuminate molecular 
components mediating JNK activation by polyQ-Htt. Regardless; inhibition of JNK activity to 
protect FAT represents a promising therapeutic target for treatment of Huntington’s disease.  
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FIGURE LEGENDS 
Figure 1: Endogenous Htt does not interact with molecular motors. A) Detergent-soluble brain 
lysates obtained from wild type (WT) and 14 month-old HdhQ109 knock-in (polyQ) mice were 
immunoprecipitated with antibodies against Htt, kinesin-1 (KHC), or dynein intermediate chains 
(DIC). Immunoblots of resulting immunoprecipates (IPP) showed that anti-kinesin-1 antibodies 
(H213) effectively precipitated both kinesin-1 heavy (KHC) and light chains (KLC), but failed to 
precipitate Htt, dynein heavy chain (DHC) or dynein intermediate chain (DIC). Similarly, anti-DIC 
antibodies (74.116) immunoprecipitated DIC and DHC, but not Htt. Conversely, anti-Htt antibodies 
effectively immunoprecipitated Htt, but not KHC, KLC, DIC or DHC. Immunoprecipitation with 
non-immune mouse IgG (NMIgG) provided a control for non-specific immunoprecipitation. An 
aliquot of each brain lysate before immunoprecipitation (Input) was used as a positive control. B) 
Detergent-soluble brain lysates from wild type (WT-Htt) and HdhQ109 knock-in (polyQ-Htt) mice 
were subjected to three cycles of immunoprecipitation with antibodies against kinesin-1. Aliquots of 
each supernatant (SN1-3) were analyzed by immunoblot. Note reductions in both KHC and KLC 
immunoreactivity with each cycle. In contrast, no change in Htt levels was detected, regardless of 
mouse genotype. Immunoprecipitations with a non-immune mouse IgG (Ctrl) served as a control 
for non-specific precipitation of proteins.  
 
Figure 2: JNK inhibitors prevent polyQ-Htt-induced FAT inhibition. Vesicle motility assays in 
isolated axoplasm show individual velocity measurements (arrowheads) as a function of time. Dark 
arrowheads and line show anterograde kinesin-dependent FAT rates and reverse grey arrowheads 
and line show retrograde, cytoplasmic dynein-dependent FAT rates. In vitro translated Htt 
constructs were perfused as before8. A) Perfusion of WT-Htt does not affect FAT8 B) Perfusion of 
polyQ-Htt inhibited both anterograde and retrograde FAT8. C) Endogenous JNK activity in squid 
axoplasm is revealed by in vitro phosphorylation assays. A time-dependent increase in cJun 
phosphorylation at JNK sites (cJun S63/73) is seen when GST-cJun is incubated with squid 
axoplasm lysates (Axo). Phosphorylation of GST-cJun is completely inhibited by either SP600125 
or JIP peptide (JIP), two well-characterized JNK inhibitors. Anti-GST antibody shows similar GST-
cJun levels for each reaction (cJun Total). Co-perfusion of polyQ-Htt with either D) SP600125 
(500nM) or E) JIP peptide (100 µM) completely prevented inhibition of FAT elicited by polyQ-Htt 
(compare D-E with B). E) In contrast, co-perfusion of polyQ-Htt with the histone deacetylase 
inhibitor BC-6-2527 (10µM) failed to prevent polyQ-Htt effects on FAT. These results indicate that 
polyQ-Htt-mediated inhibition of FAT involves activation of endogenous axoplasmic JNK. 
 
Figure 3: PolyQ-Htt increases JNK activity in Huntington’s disease models. JNK activation 
was evaluated by immunoblots with active JNK (pJNK) and total JNK (pan-JNK) antibodies, which 
mainly recognized bands at p54 and p46. A) NSC34 cells transfected with WT-Htt (18Q) or polyQ-
Htt (56Q) constructs were analyzed after 24h. Both endogenous (End) and exogenous (Exo) Htt 
were detectable. Total JNK (Pan-JNK) was similar for untransfected (Ctrl), WT-Htt (WT) and 
polyQ-Htt (polyQ) transfected cells, but phosphorylated p54 JNK (pJNK) increased with polyQ-Htt. 
B) JNK1, JNK2 and JNK3 antibody specificity were validated with GST-JNKs (left), and striatal 
lysates with individual JNK genes ablated (right). JNK1, JNK2 and JNK3 antibodies showed no 
immunoreactivity in brains from corresponding knockout samples. C) Striata from wild type (WT), 
heterozygous (Hetero) and homozygous (Homo) HdhQ109 mice showed similar Total JNK (pan-
JNK) regardless of genotype, whereas active JNK (pJNK) increased in HdhQ109 mice. Akt activation 
(p-Akt) was similar for all mice. D) Immunoblots using NSC34 (top) and mouse brain striatum 
(bottom) showed JNK1 co-migrating with p46, whereas JNK2 and JNK3 co-migrated with p54. E) 
Quantitative analysis of immunoblots in C showed activation of both p54 and p46 JNK in HdhQ109 
mice.  pJNK/JNK ratios for JNK1 (p46) or JNK2/3 (p54) indicated that both JNK2/3 and JNK1 
activity were higher in homozygous than heterozygous HdhQ109  mice. JNK2/3 was activated to a 
greater extent than JNK1, suggesting differential activation of JNKs by polyQ-Htt. Differences 
between JNK2/3 activity in WT and HdhQ109 were significant (p ≤ 0.01 in a pooled t-test). 
 
Figure 4. The effects of polyQ-Htt on FAT are mediated by JNK3. SB203580 blocks the action 
of pathogenic androgen receptor on FAT8, but SB203580 is a poor inhibitor of JNK1 (IC50≥100 
µM) and a good inhibitor of JNK2/3 (IC50≈10µM)23.  A) In vitro phosphorylation assays in 
axoplasm showed a dose-dependent inhibition of axoplasmic JNK activity by SB203580. Notably, 
significant JNK activity remained in the presence of 10µM SB203580, presumably representing 
endogenous JNK1 activity. B) In contrast, vesicle motility assays in isolated squid axoplasm show 
that effects of polyQ-Htt on FAT were blocked by SB203580 at 10µM, which is consistent with an 
action on JNK2/3. C) Sequence alignment of a JIP peptide inhibitor (Calbiochem) with portions of 
JSAP1a and JSAP1d polypeptides34. The boxed region indicates the highly conserved JNK binding 
domain (JBD).  A 31-aminoacid peptide sequence unique to JSAP1d (underlined) selectively 
interferes with binding to JNK334. D) Co-perfusion of polyQ-Htt with JSAP1a (5 µM) which blocks 
both JNK1 and JNK3 activity, effectively prevents effects of polyQ-Htt on FAT. E) Co-perfusion of 
polyQ-Htt with JSAP1d (5µM), which preferentially inhibits JNK1, only partially blocks polyQ-Htt 
effects. These results suggest that JNK3 mediates the effects of polyQ-Htt on FAT. 
 
Figure 5. Active JNK3 mimics the effect of polyQ-Htt on FAT. Effects of active, recombinant 
JNK1, JNK2 and JNK3 were evaluated by vesicle motility assays in isolated axoplasm. A) 
Perfusion of active JNK1 kinase (200nM) in axoplasm had no effect on FAT. B) Perfusion of active 
JNK2 (100nM) slightly inhibited anterograde FAT, but had no significant effect on retrograde FAT. 
C) Perfusion of JNK3 (100nM) significantly inhibited FAT in both directions, as observed with 
polyQ-Htt (compare to Fig. 2B) D) Bar graphs showing mean FAT rates in axoplasm perfused with 
active JNKs and polyQ-Htt. Error bars show SEM.  Data represent pooled FAT rate measurements 
between 30-50 min of observation. Anterograde FAT rates after polyQ-Htt perfusion were 
comparable to those elicited by perfusion of active JNK3 and both JNK3 and polyQ-Htt 
significantly inhibit retrograde FAT.  
 
Figure 6. JNK3 phosphorylates kinesin-1 heavy chains at Ser176. A) Mass spectrometry studies 
identified a tryptic peptide within the motor domain of kinesin-1 (amino acids 173-188) showing 
unequivocal evidence of phosphorylation by JNK3 (see also Supplemental Fig. 2). B) 
Recombinant KHC584-WT protein was incubated in the presence (+) or absence (-) of active JNK3 
and 32P-ATP, and analyzed by SDS-PAGE. The ability of JNK3 to phosphorylate KHC584 at S175 
and S176 was also evaluated using KHC584-S175 and KHC584-S176A mutants. An autoradiogram 
(32P) showed a dramatic reduction in the phosphorylation of a KHC584-S176A (S176A) construct 
relative to wild type (WT) and KHC584-S175A (S175A) constructs (arrow). Coomassie blue (CB) 
staining showed comparable amounts of KHC584 in all lanes. Asterisk indicates autophosphorylated 
JNK3. These results indicated that S176 is the main residue phosphorylated by JNK3.  
 
Figure 7. PolyQ-Htt expression inhibits kinesin-1 binding to microtubules. A) Lysates of 
NSC34 cells transfected with WT-Htt or polyQ-Htt as in Fig. 3A were analyzed by immunoblot. 
Total levels (Input) of kinesin-1 (KHC), dynein heavy chain (DHC) and tubulin (Tub) were 
comparable for untransfected (Ctrl), WT-Htt and polyQ-Htt-expressing cells. However, the fraction 
of kinesin-1 recovered in association with microtubules was reduced for lysates from polyQ-Htt 
expressing cells, when compared to untransfected and WT-Htt-expressing cells. B) Microtubule-
binding assays using recombinant kinesin-1 (KHC584). Immunoblot (WB) shows that 
unphosphorylated KHC584 is mainly recovered in association with microtubules (Pellet). An 
autoradiogram (32P) reveals a significant fraction of JNK3-phosphorylated KHC584 remains in the 
supernatant.  
Figure 8.  A mutation mimicking Ser176 phosphorylation reduces the translocation efficiency 
of constitutively active kinesin-1 in cultured hippocampal neurons.  A-F:  Representative stage 
3 neurons were co-transfected with GFP-tagged constructs encompassing the first 560 amino acids 
of kinesin-1 (KHC560, A, C, and E) and mCherry, a soluble marker protein that diffuses throughout 
the cell (B, D, and F, scale bar= 20µm). Cells were fixed with formaldehyde and imaged 5 hours 
after transfection. Wild type (WT, A) and non-phosphorylatable S176A mutant (S176A, E) 
constructs efficiently translocated so that they were localized almost exclusively at the axon tip. In 
contrast, a significant fraction of the pseudophosphorylated S176 mutant (S176E, C) was found 
throughout the cell body. Arrowheads in A, C and E indicate the location of the neuronal cell 
bodies as seen in B, D, and F. G:  The percentage of total KHC560-GFP fluorescence localized at the 
axon tip was measured in cells expressing KHC560 WT (N=22), KHC560 S176E (N=33) or KHC560 
S176A (N=30).  Significantly less KHC560 S176E accumulated at axon tips with the wild-type 
construct (t-test, p<0.0001); only marginally less KHC560 S176A accumulated at the axon tip than 
the wild-type construct (t-test, p~0.05).  Bars show mean and standard deviation. 
 
 
SUPPLEMENTAL FIGURES 
Supplemental Figure 1. PolyQ-Htt does not affect motor protein solubility. A) Brain lysates 
from wild type and HdhQ109 knock-in mice expressing endogenous levels of normal (WT-Htt) or 
pathogenic Htt (polyQ-Htt) were fractionated into detergent (TX-100) soluble and insoluble 
fractions. The distribution of major subunits of conventional kinesin and cytoplasmic dynein 
subunits were analyzed by immunoblot:  Kin: (kinesin-1, kinesin heavy chain), DHC (dynein heavy 
chain); DIC: (dynein intermediate chain), Note that while Huntingtin (Htt) protein partitions 
similarly in both fractions, the bulk of molecular motors was recovered in the supernatant fraction. 
There was no evidence of increased motor protein insolubility induced by polyQ-Htt expression. B) 
Detergent-soluble brain lysates from wild type (WT-Htt) and HdhQ109 knock-in (polyQ-Htt) mice 
were subjected to three cycles of immunoprecipitation with antibodies against DIC, as in Fig. 1B. 
Aliquots of input material (Input) or the supernatant after three immunoprecipitation cycles (SN3) 
were analyzed by immunoblot with antibodies against DIC and Htt. Note the marked depletion of 
DIC immunoreactivity after immunoprecipitation with DIC-specific antibodies. Immunoprecipitates 
with a non-immune IgG (Ctrl) served as a control for non-specific precipitation of proteins in these 
experiments. In contrast, no change in Htt levels was detected, regardless of mouse genotype. 
 
Supplemental Figure 2. Mass spectrometry analysis of kinesin-1. A) Diagram of mass 
spectrometry protocols for analysis of kinesin-1 phosphorylation by JNK3 and JNK1. B) The amino 
acid sequence of the KHC584 construct is shown. Residues in red indicate amino acid coverage 
(72%). The sequence corresponding to the motor domain of kinesin-1c (KIF5C) is outlined. The 
major phosphopeptide identified in these studies (amino acids 173-188) is marked in bold. C) 
Relevant details of the 173-188 phosphopeptide identification are shown including its sequence (e), 
charge (a), mass (b), cross correlation (c), and delta correlation (d) values (top). Mass spectrum of 
the 173-188 phosphopeptide. The graph plots ion intensity vs. mass (M) ion charge (Z) ratio for b+ 
(red) and y+ (blue) ions.  The peptide sequence (top) shows a detail of the identified residues.  
 
Supplemental Figure 3. KHC584 motor domain is phosphorylated by JNK3, but not by JNK1. 
KHC584 was phosphorylated in vitro using either JNK3 or JNK1 (as shown in Figure 7B), and 
samples processed for mass spectrometry analysis as described in Material and Methods.  Full 
spectra (Full ms) corresponding to the retention time of the 173-188 phosphopeptide (RT: 58.44 
minutes) are shown. The red arrow points the peak corresponding to the precursor ion of the 
phosphopeptide (m/z of 930.4). Note that this peak is present only in Full ms of JNK3-
phosphorylated KHC584 samples (left), but not in Full ms of JNK1-phosphorylated KHC584 samples 
(right). The black arrow and dashed red line point the area of the Full ms where the peak for the 
precursor ion should be found. The activities of recombinant JNK1 and JNK3 were normalized 
using c-Jun as a substrate. These results indicate that JNK3, but not JNK1, can phosphorylate the 
Ser176 residue in kinesin-1.  
 
Supplemental Figure 4. Ser176 is a conserved residue in the Kinesin-1 microtubule-binding 
domain. A) Sequence alignment shows that Ser176 (boxed) is conserved among human, mouse and 
squid sequences for kinesin-1.  B) Ser176 is located in a surface loop of KHC motor domain, a 
region implicated in binding of kinesin-1 to microtubules36.  
 
Supplemental Figure 5.  JNK3 phosphorylation of KHC584 reduces binding to microtubules. 
The histogram shows quantitation of immunoblots and autoradiograms in Figure 7B. The ratio of 
KHC584 in microtubule pellets and supernatants (P/S) reveals a dramatic reduction in KHC binding 
to microtubules upon phosphorylation by JNK3. 
Supplemental Figure 6. Inhibition of conventional kinesin-based motility induced by 
pathogenic Htt (polyQ-Htt).  Our results showing increased activation and phosphorylation of 
JNKs induced by polyQ-Htt suggest that this mutant polypeptide activates specific MAPKKKs and 
MAPKKs (dashed arrow) upstream of JNK. Increased JNK1 activation is linked to alterations in the 
activity of various transcription factors (i.e., ATF-2 and c-Jun, among others), consistent with 
widely reported changes in gene transcription in Huntington’s disease49.  Activation of JNK3 on the 
other hand, would lead to phosphorylation of kinesin-1 and likely other axonal substrates (question 
mark). Data in this work indicates that phosphorylation of kinesin-1s by JNK3 results in reduced 
binding of conventional kinesin to microtubules. Reductions in the delivery of critical axonal 
cargoes by conventional kinesin would result in impaired synaptic function and dying-back 
degeneration of neurons3. 
 
Supplemental Figure 7: Characterization of antibodies used in this study. A) Immunoblot 
analysis of whole mouse brain lysates using antibodies against molecular motors. From left to right: 
HTT: anti-huntingtin (2166, Chemicon); DHC), anti-dynein heavy chain (Santa Cruz #9115); DIC: 
anti-dynein intermediate chain (clone 74.1, Santa Cruz #13524); H2: anti-kinesin heavy chain (H2 
clone, Chemicon)13; 63-90: anti-pan KLCs (63-90 clone, Chemicon)13. B) Immunoblot analysis of 
mouse striatum lysates using antibodies against JNKs. Pan-JNK: anti-pan-JNK (Upstate #06-748); 
pJNK: anti-phospho JNK (Cell Signaling #9251); JNK1: anti-JNK1 (Pharmingen #554268); JNK2:  
anti-JNK2 (Cell Signaling #4672); JNK3: anti-JNK3 (Cell Signaling #2305). C) Immunoblot 
analysis of NSC34 lysates using antibodies against JNKs. Antibodies are the same as in B. 
Molecular weight markers (Invitrogen#LC5925) are indicated at the left side of each panel. See 
Material and methods for a detailed description of SDS-PAGE conditions.
MATERIAL AND METHODS 
Antibodies and Reagents: The following antibodies were used: anti-KHC (H2 clone, Chemicon)13, 
anti-pan KLCs (63-90 clone, Chemicon)13, anti-dynein intermediate chain (Santa Cruz #13524), 
anti-dynein heavy chain (Santa Cruz #9115), anti-phospho Akt (44-622G, Biosource), anti-Htt 
(2166, Chemicon), anti-pan-JNK (Upstate #06-748), anti-JNK1 (Pharmingen #554268), anti-JNK2 
(Cell Signaling #4672), anti-JNK3 (Cell Signaling #2305), anti-phospho JNK (Cell Signaling 
#9251), anti-GST (Sigma #G7781), anti-phospho c-Jun (Santa Cruz #16312), anti-tubulin (DM1A, 
Sigma). All antibodies were characterized for specificity against the tissues used (see Supplemental 
Figure 7). The following secondary antibodies were used: Jackson 111-035-045 HRP-conjugated 
goat anti-rabbit, Jackson 115-035-146 HRP-conjugated goat anti-mouse IgG, and Jackson 805-035-
180 HRP-conjugated bovine anti-goat IgG. 
SB203580, SP600125 (JNK inhibitor II), okadaic acid, staurosporine, K252a, 50nM okadaic acid, 
microcystin and c-Jun were obtained from Calbiochem. The HDAC inhibitor BC-6-2527 was a 
generous gift from Alan Kozikowski (UIC). Inhibitor stocks were prepared in DMSO. Active JNK 
kinases were from Upstate (JNK1 #14-327, JNK2 #14-329, and JNK3 #14-501). His-tagged KHC584 
protein constructs were expressed in BL21-Codon Plus (DE3) E. coli (Stratagene), and purified 
using Talon beads (Clontech). Trx-tagged JSAP1 polypeptides were expressed and purified as 
described before34. 
Immunoblots: Proteins were separated by SDS-PAGE on 4-12% Bis-Tris gels (NuPage minigels, 
Invitrogen), using MOPS Running Buffer (Invitrogen) and transferred to PVDF using Towbin 
buffer supplemented with 10% (v/v) methanol (90 minutes at 400mA using Hoeffer TE22 
apparatus). Immunoblots were blocked with 1% (w/v) non-fat dried milk in TBS (25 mM Tris pH 
7.2, 2.68 mM KCl, 136.8 mM NaCl). Membranes were incubated with primary antibodies overnight 
at 4º C in 1% IgG free-BSA (Jackson Immunoresearch), and washed four times with 0.1% Tween-
20 in TBS. Primary antibody binding was detected with HRP-conjugated anti-mouse, anti-rabbit or 
anti-goat antibodies  (Jackson Immunoresearch), and visualized by chemiluminescence (ECL, 
Amersham). Quantitative immunoblotting was performed as before39. 
Immunoprecipitation: Mouse brains from wild-type and HdhQ109 knock-in mice were homogenized 
in lysis buffer (LB; 25 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, and mammalian protease 
inhibitor cocktail (Sigma, 1/100 dilution)]. Lysates were centrifuged twice for 5 minutes at 55,000 
rpm (163,640 gmax) using a TLA 100.3 rotor (Beckman Instruments, Palo Alto, CA). The resulting 
supernatant fractions were precleared using a mixture of Protein G agarose beads (Pierce), and non-
immune mouse IgG-conjugated Sepharose beads (Jackson Immunoresearch) for 1 hour at RT. 400 
µg of each precleared brain lysate were brought to 1 ml with LB, and incubated with 5µg of the 
appropriate antibody plus 10µl of Protein G agarose beads at 40 C for 3hs.  Immunocomplexes were 
recovered by centrifugation (3000 gmax for 30 seconds), washed four times with 1 ml LB, once with 
50mM HEPES pH 7.4, and resuspended in Laemmli buffer.  For immunodepletion experiments 
(Fig. 1B and supplemental Fig. 1B), precleared mouse brain lysates were subject to three cycles of 
immunoprecipitation with H2 or DIC antibodies as above. After each immunoprecipitation cycle, a 
50µl aliquot of each supernatant was saved for immunoblot analysis, as before13, 14. 
Vesicle Motility assays in isolated axoplasm: Axoplasm was extruded from giant axons of the 
squid Loligo pealii (Marine Biological Laboratory) as described previously7, 8. Recombinant 
proteins, peptides or inhibitors were diluted into X/2 buffer (175 mM potassium aspartate, 65 mM 
taurine, 35 mM betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl2, 5 mM EGTA, 1.5 mM 
CaCl2, 0.5 mM glucose, pH 7.2) supplemented with 2-5 mM ATP and 20 µl added to perfusion 
chambers. Preparations were analyzed on a Zeiss Axiomat with a 100X, 1.3 n.a. objective, and DIC 
optics. Hamamatsu Argus 20 and Model 2400 CCD camera were used for image processing and 
analysis. Organelle velocities were measured with a Photonics Microscopy C2117 video 
manipulator (Hamamatsu). 
Recombinant Constructs: Expression vectors encoding amino acids 1–548 of human Htt with an N-
terminal FLAG epitope tag were translated in vitro as described previously8, and used for vesicle 
motility assays. Expression vectors encoding amino acids 1-969 of human Htt (wild type (Q16) and 
pathogenic (Q46)) with an N-terminal FLAG tag were used for transfection studies (Fig. 3A and 
7A)29. His-tagged KHC584-S176A, KHC584-S176A, and GFP-tagged KHC560 mutant constructs were 
generated using the Quick-site mutagenesis kit (Stratagene). 
Axoplasmic JNK activity assays: For experiments on kinase activity in axoplasm (Figs. 2C and 
4A), 3- 4 axoplasms were triturated in 280µl of KB buffer (KB: 10mM Hepes pH 7.4, 10mM 
MgCl2, 1mM DTT) minus ATP. Reactions (50µl) were incubated at RT and started by adding ATP 
(50µM). Aliquots were collected at various time points up to 20 minutes and analyzed by 
immunoblotting. 
Brain Tissue/Cell lysate preparation: Mouse brain tissue and cultured cells were homogenized in 
ROLB buffer [10mM Hepes pH7.4, 0,5% Triton X-100, 80mM β-glycerophosphate, 50mM Sodium 
Fluoride, 2mM Sodium Orthovanadate, 100nM Staurosporine, 100nM K252a, 50nM Okadaic acid, 
50nM Microcystin, 100mM Potassium Phosphate and mammalian protease inhibitor cocktail 
(Sigma)]. Lysates were clarified by centrifugation, and protein concentration determined using BCA 
kit (Pierce). All mouse use was under protocols approved by the Institutional Animal Care and Use 
Committee at UIC and followed NIH guidelines for vertebrate animal use. 
NSC34 Cell Culture and Transfection:  NSC34 cells were plated at 10,000 cells/cm2 on 10 cm 
tissue culture dishes for biochemical studies and grown on DMEM containing 1mM glutamine and 
10% Fetal Bovine Serum (Hyclone). When cells reached 60-70% confluency, media was replaced 
by DMEM plus 1mM glutamine, and cells transfected with WT-Htt and polyQ-Htt constructs (1-
969)29 using Lipofectamine 2000 (Invitrogen), as previously described39. JNK activation was 
evaluated 24h after transfection.  
Microtubule-binding Assays: NSC34 cells were transfected with WT-Htt and polyQ-Htt constructs 
as described above. After 24 hours, cells were scraped in BRB80 buffer [80 mM PIPES pH 7, 1 mM 
MgCl2, 1 mM EGTA, 1 µM staurosporine, 1 µM K252a, 50 nM okadaic acid, 200 nM microcystin, 
1/100 dilution of phosphatase inhibitor cocktail II (Calbiochem), and1/100 dilution of mammalian 
protease inhibitor cocktail (Sigma)] at 40C, and homogenized using a 30g syringe (500µl of 
BRB80/10 cm dish). Lysates were centrifuged at 14,000 rpm in a tabletop centrifuge for 5 minutes, 
and centrifuged at 55,000 rpm in TLA100.3 rotor for additional 5 minutes. 700 µg of total protein 
from clarified supernatants were incubated with 0.2 mg of taxol-stabilized microtubules and 2.5 
mM AMP-PNP (Sigma) for 30 min at 37 ºC.  The mixture above was loaded on top of a cushion 
made of 20% sucrose in BRB80 buffer, and centrifuged for 15 minutes at 50,000 rpm using a 
Beckman TLA-100.3 rotor at room temperature. Microtubule-enriched pellets were resuspended in 
Laemmli buffer and analyzed by immunoblotting. For microtubule binding experiments (Fig. 7B), 
4µl aliquots of in vitro-phosphorylated KHC584 (prepared as above) were incubated with 64µg of 
taxol-stabilized microtubules in BRB80 buffer and either 2mM AMP-PNP or 2mM ATP (100µl 
total volume). After 30 minutes incubation, these mixtures were centrifuged for 15 minutes at 
50,000 rpm over a cushion of 20% in BRB80 in a Beckman TLA-100.3 rotor at 37° C. Pellets and 
supernatants were collected, and the levels of kinesin in each fraction quantified by phosphorimager 
scanning of radioactivity or with fluorescently-labeled secondary antibodies. 
Kinesin-1 Translocation Assays: Accumulation of KHC560-GFP-WT and KHC560-GFP-S176E 
constructs in neurites of cultured hippocampal neurons was evaluated as before37. 
Statistical Analysis. All experiments were repeated at least 3 times. Unless otherwise stated, the 
data was analyzed by ANOVA followed by post-hoc Student-Newman-Keul’s test in order to make 
all possible comparisons. Data was expressed as mean + SEM and significance was assessed at 
p<0.05 or 0.01 as noted. 
Mouse Brain Fractionation: Brains from wild-type (12 months old) and HdhQ109 knock-in (14 
months old) were homogenized in 3mls of HB buffer (50mM Hepes pH 7.4, 150 mM NaCl, 1% 
Triton X-100) and centrifuged 2X 2,500g for 10 minutes, and 1X at 7,000g for 10 minutes to pellet 
debris and nuclei. Clarified lysates were spun at 150,000g for 20 minutes, in a Beckman TLA 100.3 
rotor at 55,000 RPM. The pellets and supernatant represented detergent insoluble and detergent-
soluble fractions, respectively. Detergent insoluble pellets were resuspended in HB. Equal amounts 
of protein from each fraction were analyzed by immunoblotting. 
In vitro Phosphorylation: In vitro phosphorylation experiments (40 µl volume) were performed by 
incubating KHC584 protein constructs (3 µM) with 0.1µM JNK3 (Upstate) or 0.2µM JNK1 (Upstate) 
in HEM buffer (50 mM HEPES, 12 mM MgSO4, 100 µM ATP pH 7.4), as previously described7.  
Mass Spectrometry Studies: Phosphorylated KHC584 protein was subjected to in solution trypsin 
digestion. Briefly, dried samples were resuspended in 30 mM Hepes, 30 mM NaF in the presence of 
1 µg of trypsin (Sigma, proteomics grade) and incubated at 37° C overnight (16-18h). The resulting 
tryptic peptides were later resuspended in buffer A (5% acetonitrile, 0.4% acetic acid, 0.005% of 
HFBA in water) for mass spectrometry analysis or prepared for IMAC35. Samples were analyzed by 
liquid chromatography on line with a LTQ (a two-dimensional ion trap) instrument equipped with a 
commercial nanospray source (Thermo Finnigan, San Jose, CA). Samples were automatically 
loaded by a microautosampler (Famos, LC Packings, Sunnyvale, CA) onto an 11-cm x 100µm 
fused silica capillary column packed with reverse C18 material (5-µm, 100-Å Magic beads, 
Michrom Bioresources, Auburn, CA). The solvent system was delivered by an HP1100 pump 
(Agilent Technologies, Palo Alto, CA). Samples were analyzed by performing full scan followed by 
tandem MS or MS/MS or MS2 of the 5 most intense ions (top 5) by collision induced dissociation 
(CID). Sample loading, solvent delivery, and scan function were controlled with Xcalibur software 
(Thermo Finnigan). Liquid chromatography tandem mass spectrometry files were searched using 
SEQUEST algorithm against a generated database containing KIF5C_Rat and KIF5C_Mouse, 
among others proteins.  SEQUEST search parameters included mass tolerance of ±1.5 Da, trypsin 
specificity, and differential search for serine, threonine and tyrosine phosphorylation. The generated 
data set was filtered using INTERACT50 based on the following criteria: delta correlation, dCn: 0.1, 
X correlation value for +1 peptides ≥ 1.8, +2 ≥ 2.2 and +3 ≥ 3.2. 
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